IBC Speakers Predict Reimbursement Woes For Personalized Diagnostic Tests
This article was originally published in The Gray Sheet
Variation in local Medicare coverage policies for Genentech's Herceptin demonstrates the difficulty CMS will face as predictive molecular diagnostic test use becomes more prevalent, according to Covance VP-Health Economics and Outcome Services David Parker
You may also be interested in...
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.